CDTX - Cidara Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.0900
-0.0400 (-1.88%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.1300
Open2.1600
Bid0.0000 x 3100
Ask0.0000 x 1100
Day's Range2.0500 - 2.1650
52 Week Range1.2230 - 4.9500
Volume198,567
Avg. Volume443,088
Market Cap65.938M
Beta (3Y Monthly)2.05
PE Ratio (TTM)N/A
EPS (TTM)-2.1430
Earnings DateAug 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.83
Trade prices are not sourced from all markets
  • GlobeNewswire

    Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

    SAN DIEGO, Sept. 16, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that.

  • Benzinga

    Wedbush Recommends Buying Cidara Shares After Rezafungin Deal

    Cidara Therapeutics Inc (NASDAQ: CDTX ) announced a development and commercialization deal Tuesday for its lead antifungal investigational drug, rezafungin. The Analyst Wedbush analyst Robert Driscoll ...

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For September 4, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Cidara Therapeutics (NASDAQ: CDTX ) shares ...

  • Thomson Reuters StreetEvents

    Edited Transcript of CDTX earnings conference call or presentation 8-Nov-17 9:05pm GMT

    Q3 2017 Cidara Therapeutics Inc Earnings Call

  • MarketWatch

    Cidara Therapeutics's stock rockets after commercialization deal with a potential value of up to $568 million

    Shares of Cidara Therapeutics Inc. rocketed 67% in active premarket trading Tuesday, after the biotechnology company announced a partnership with Mundipharma with a total potential value of $568 million to Cidara. Under terms of the agreement, which follows the completion of its phase 2 trial of Rezafungin for the treatment of fungal infections, Cidara will receive a $30 million upfront payment and Mundipharma will make a $9 million equity investment in Cidara, while Cidara will grant Mundiphama exclusive commercialization rights to rezafungin outside of the U.S. and Japan. Cidara will also receive $42 million in near-term funding to support phase 3 trials, and Cidara will be eligible to receive development, regulatory and commercial milestone payments. "This is a transformational collaboration for Cidara, and we look forward to working closely with our colleagues at Mundipharma, a highly successful, profitable company with a commercial presence spanning 120 markets worldwide and annual sales exceeding EUR2 billion," said Cidara Chief Executive Jeffrey Stein. Cidara's stock has tumbled 28.5% year to date through Friday, while the iShares Nadsaq Biotechnology ETF has gained 6.7% and the S&P 500 has advanced 16.7%.

  • Business Wire

    Cidara Therapeutics to Present Data from its Cloudbreak Antiviral Program at the Options X for the Control of Influenza Conference

    Cidara Therapeutics, Inc. , a biotechnology company developing novel anti-infectives including immunotherapies, today announced that five abstracts, including one late-breaker, highlighting data from its Cloudbreak® antiviral program have been accepted for presentation at the Options X for the Control of Influenza conference taking place August 28-September 1 in Singapore.

  • GlobeNewswire

    Cidara Provides Corporate Update and Reports Second Quarter 2019 Financial Results

    SAN DIEGO, Aug. 08, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported.

  • GlobeNewswire

    Cidara Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019, at 10:20 a.m. EDT (7:20 a.m. PDT) in New York City. Cidara is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. Cidara is currently advancing its novel echinocandin antifungal, rezafungin acetate, in a Phase 3 clinical trial for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE).

  • GlobeNewswire

    Cidara Therapeutics Reports Positive Topline Results in Phase 2 STRIVE B Trial of Antifungal Rezafungin

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported positive topline results from Part B of the global Phase 2 STRIVE trial evaluating the company’s lead antifungal candidate rezafungin. In the STRIVE B trial, rezafungin met all of its objectives for efficacy, safety and tolerability in the treatment of patients with candidemia and/or invasive candidiasis. Rezafungin is a novel echinocandin antifungal being developed as a once-weekly therapy for the first-line treatment and prevention of serious invasive fungal infections.

  • PR Newswire

    X-Biotix Therapeutics Joins Antimicrobials Working Group

    WASHINGTON , July 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to ...

  • PR Newswire

    Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019

    64 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 20, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...

  • Imagine Owning Cidara Therapeutics (NASDAQ:CDTX) And Trying To Stomach The 85% Share Price Drop
    Simply Wall St.

    Imagine Owning Cidara Therapeutics (NASDAQ:CDTX) And Trying To Stomach The 85% Share Price Drop

    As an investor, mistakes are inevitable. But you want to avoid the really big losses like the plague. So spare a...

  • PR Newswire

    Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections

    The DISARM Act of 2019 provides the framework needed to stabilize the antimicrobial ecosystem, spur development of new infection-fighting drugs, and preserve the effectiveness of existing medicines for ...

  • Business Wire

    Cidara Therapeutics to Present New Data on Rezafungin and its Cloudbreak Antiviral Candidate for Influenza at ASM Microbe 2019

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data from studies of rezafungin, the company’s Phase 3 antifungal, and CB-012, its Cloudbreak® antiviral Fc-conjugate (AVC) candidate for influenza, will be presented at the American Society for Microbiology (ASM) Microbe 2019 annual meeting taking place June 20-24 in San Francisco.

  • What Makes Cidara Therapeutics (CDTX) a New Buy Stock
    Zacks

    What Makes Cidara Therapeutics (CDTX) a New Buy Stock

    Cidara Therapeutics (CDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • Associated Press

    Cidara Therapeutics: 1Q Earnings Snapshot

    The San Diego-based company said it had a loss of 60 cents per share. In the final minutes of trading on Thursday, the company's shares hit $2.15. A year ago, they were trading at $4.03. _____ This story ...

  • GlobeNewswire

    Cidara Provides Corporate Update and Reports First Quarter 2019 Financial Results

    SAN DIEGO, May 09, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported.

  • Business Wire

    Cidara Therapeutics Highlights New Data from Multiple Rezafungin Studies Presented at ECCMID 2019

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, highlighted new data from multiple studies of rezafungin, the company’s lead investigational compound, this week during the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands. Rezafungin is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. Three oral presentations at ECCMID showcased results from nonclinical and in vivo studies that demonstrate the potential of rezafungin to fight and protect against difficult-to-treat fungal infections.

  • Business Wire

    Cidara Therapeutics Selects First Clinical Development Candidate from its Cloudbreak Influenza (Antiviral) Program

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company has selected the antiviral conjugate (AVC) CB-012 as its first clinical development candidate from the company’s Cloudbreak® influenza (antiviral) program. Data supporting the selection will be presented today in an oral session at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). CB-012 is a novel conjugate of a highly potent antiviral agent linked to a human antibody fragment.

  • PR Newswire

    Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    78 Presentations by Coalition Members During the Annual Meeting WASHINGTON , April 12, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...

  • GlobeNewswire

    Cidara Therapeutics to Present at the 18th Annual Needham Healthcare Conference

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019, at 11:20 a.m. EDT (8:20 a.m. PDT) in New York City. Cidara is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. Cidara is currently advancing its novel echinocandin antifungal, rezafungin acetate, in a Phase 3 clinical trial, for the treatment of candidemia and invasive candidiasis and continues to discuss with regulatory authorities its plans for the design and the initiation of a second Phase 3 trial in the prophylaxis of invasive fungal infections in patients undergoing allogeneic blood and marrow transplantation.

  • Business Wire

    Cidara Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    Six poster presentations include new analyses from Phase 2 STRIVE clinical trial of rezafungin

  • Business Wire

    Cidara Therapeutics Announces Rezafungin Presentations at the 2019 European Society for Blood and Marrow Transplantation Meeting

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that three rezafungin abstracts have been accepted for presentation at the 45th Annual European Society for Blood and Marrow Transplantation (EBMT) Meeting to be held in Frankfurt, Germany from March 24-27, 2019. Rezafungin is a novel echinocandin antifungal and is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. “Patients undergoing blood and marrow transplantation are at increased risk of acquiring deadly invasive fungal infections and current prevention strategies require multiple antifungals that are associated with known drug-drug interactions as well as safety and tolerability issues,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.

  • Have Insiders Been Buying Cidara Therapeutics, Inc. (NASDAQ:CDTX) Shares?
    Simply Wall St.

    Have Insiders Been Buying Cidara Therapeutics, Inc. (NASDAQ:CDTX) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examplesRead More...

  • GlobeNewswire

    Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results

    SAN DIEGO, Feb. 28, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported.